NURO VS CYCN Stock Comparison

Performance

NURO
10/100

NURO returned -70.24% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

CYCN
10/100

CYCN returned -80.58% in the last 12 months. Based on SPY's performance of -13.85%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

NURO
63/100

2 analysts offer 12-month price targets for NURO. Together, they have an average target of 0, the most optimistic target put NURO at 0 within 12-months and the most pessimistic has NURO at 0.

CYCN

"Analyst Price Targets" not found for CYCN

Technicals

NURO
36/100

NURO receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

CYCN
14/100

CYCN receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

NURO
100/100

NURO has missed earnings 0 times in the last 20 quarters.

CYCN
10/100

CYCN has missed earnings 6 times in the last 20 quarters.

Profit

NURO
10/100

Out of the last 20 quarters, NURO has had 1 profitable quarters and has increased their profits year over year on 0 of them.

CYCN
10/100

Out of the last 20 quarters, CYCN has had 0 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

NURO
51/100

NURO has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.

CYCN
54/100

CYCN has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

All score calculations are broken down here to help you make more informed investing decisions

NeuroMetrix, Inc. Common Stock Summary

Nasdaq / NURO

Healthcare

Medical - Devices

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Cyclerion Therapeutics, Inc. Common Stock Summary

Nasdaq / CYCN

Healthcare

Biotechnology

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Power up your portfolio